Spelling suggestions: "subject:"scavenging receptor""
11 |
The Scavenger Receptor B1 is a multifunctional HCV entry factor / Le « Scavenger Récepteur B1 » est un facteur multifonctionnel de l'entrée cellulaire pour le virus de l'hépatite CDao Thi, Viet Loan 13 October 2011 (has links)
L’entrée cellulaire du virus de l’Hépatite C (VHC) est un processus complexe qui met en jeu plusieurs facteurs cellulaires. L’un d’eux est un récepteur des lipoprotéines, le « Scavenger Récepteur B1 » (SR-BI). SR-BI a initialement été proposé comme récepteur viral de par son interaction avec la glycoprotéine (GP) E2 du VHC. L’importance de SR-BI pour l’entrée cellulaire du VHC n’était, jusqu’alors suggérée que par des preuves indirectes. En outre, les mécanismes par lesquels SR-BI permet l’entrée du VHC restent peu connus. Néanmoins, grâce à l’identification de cellules hépatiques présentant un très faible niveau d’expression - non détectable - de ce récepteur et devenant susceptibles à l’infection par le VHC par l’expression ectopique de SR-BI, nous avons clairement démontré que SR-BI est indispensable pour l’entrée du VHC. Afin d’étudier le rôle de SR-BI dans l’entrée cellulaire du VHC, qui présente une singulière hétérogénéité en terme de propriétés biochimiques et de composition en protéines cellulaires intégrées à la surface des particules virales, celles-ci ont été séparées par centrifugation analytique en gradient de densité. Nous avons ainsi défini trois fonctions de SR-BI permettant l’entrée de sous-populations du VHC. D’un part, une fonction d’attachement, correspondant à la capture des particules de densités intermédiaires à la surface cellulaire. Cet attachement résulte de l’interaction entre SR-BI et des composants des lipoprotéines présents à la surface des particules virales, sans mettre en jeu d’interaction avec les GP virales. D’autre part, nous avons défini une fonction d’accès, requise pour toutes les sous-populations du VHC. Cette fonction, elle aussi indépendante de l’interaction directe entre la GP E2 et SR-BI, requiert la fonction physiologique de transfert de lipides de SR-BI. En effet, le blocage de cette fonction de transfert à l’aide de molécules inhibitrices ou par insertion de mutations invalidantes de SR-BI réduit significativement l’entrée du VHC. Enfin, nous avons mis en évidence une troisième fonction, appelée fonction de stimulation, nécessitant l’interaction de la GP E2 et SR-BI, ainsi que la fonction de transfert lipidique deSR-BI et qui, par ailleurs, est régulée par des composants des lipoprotéines. Par l’analyse fonctionnelle de mutants, nous avons défini des déterminants viraux, dans la région HVR1 à l’extrémité N-terminale de la GP E2, et cellulaires, dans la partie N-terminale de SR-BI, critiques pour l’interaction entre E2 et SR-BI et, par conséquent, régulent la fonction destimulation. En conclusion, nous avons démontré que le VHC exploite SR-BI de diverses façons et via des interactions à la fois avec des composants viraux et cellulaires incorporés dans les particules du VHC et ainsi permet l’entrée de particules virales très hétérogènes. / Hepatitis C virus (HCV), which is characterised by its highly heterogeneous biophysical properties, is thought to enter the cell in a slow and multistep manner involving several cell surface molecules. One of these cellular molecules is the Scavenger Receptor B1 (SR-BI), which was identified as an HCV receptor due to its interaction with the HCV glycoprotein E2.Until now, the exact usage of SR-BI by HCV and SR-BI mediated mechanism during cell entry remained unknown. In order to understand SR-BI functions during HCV cell entry, we wanted to study (1) the relevance of HCV E2 binding to SR-BI, (2) the implication of the physiological function of SR-BI itself and (3) how SR-BI mediates cell entry of heterogeneous HCV particles. Owing to the identification of two cell lines that express very low levels of endogenous SRBI, receptor complementation assays revealed, that the ectopic expression of SR-BI is indispensible for HCV entry. Accordingly, we showed for the first time, that SR-BI is an essential HCV entry factor. In order to study HCVcc populations that differ in biophysical properties and host protein composition, we separated them by density gradient analysis and assigned three different SR-BI functions to entry of particular HCV sub-populations. First, an attachment function, that leads to the initial capture of HCV particles of intermediate densities to the cell surface. This attachment function is mediated by an interaction between SR-BI and lipoprotein components on the viral particles but not by the viral glycoproteins. Second, we defined an access function, which is important for all different HCV sub-populations. This access function is also not dependent on the interaction between HCV E2 and SR-BI but involves the physiological function of the receptor. Blocking the lipid transfer function of SRBI upon either mutation or by a specific inhibitor abrogated strongly HCV entry. Finally we defined a third function of SR-BI, that we call enhancement function. This function is triggered upon E2-SR-BI interaction, is dependent on lipoprotein components and involves the lipid transfer function of SR-BI. Upon functional mutagenesis studies, we identified as critical determinants HVR1 (Hypervariable Region 1) residues in E2 and the N-terminus of SR-BI, allowing E2-SR-BI interaction and consequently the implementation of the enhancement function. In conclusion we demonstrate that SR-BI is an unparalled virus entry factor. Its usage by HCV to enter the cell is manifold and intriguingly, owing to the heterogeneous nature of HCV particles, involves different viral components exploiting different aspects of SR-BI.
|
12 |
Scavenger Receptor-A (CD204): A Two-Edged Sword in Health and DiseaseKelley, Jim L., Ozment, Tammy R., Li, Chuanfu, Schweitzer, John B., Williams, David L. 01 January 2014 (has links)
Scavenger receptor A (SR-A), also known as the macrophage scavenger receptor and cluster of differentiation 204 (CD204), plays roles in lipid metabolism, atherogenesis, and a number of metabolic processes. However, recent evidence points to important roles for SR-A in infammation, innate immunity, host defense, sepsis, and ischemic injury. Herein, we review the role of SR-A in infammation, innate immunity, host defense, sepsis, cardiac and cerebral ischemic injury, Alzheimer's disease, virus recognition and uptake, bone metabolism, and pulmonary injury. Interestingly, SR-A is reported to be host protective in some disease states, but there is also compelling evidence that SR-A plays a role in the pathophysiology of other diseases. These observations of both harmful and beneficial effects of SR-A are discussed here in the framework of inflammation, innate immunity, and endoplasmic reticulum stress.
|
13 |
Scavenger receptor class-A has a central role in cerebral ischemia-reperfusion injuryLu, Chen, Hua, Fang, Liu, Li, Ha, Tuanzhu, Kalbfleisch, John, Schweitzer, John, Kelley, Jim, Kao, Race, Williams, David, Li, Chuanfu 01 December 2010 (has links)
The innate immune response is involved in the pathophysiology of cerebral ischemia-reperfusion (I/R) injury. Recent evidence suggests that scavenger receptors have a role in the induction of innate immunity. In this study, we examined the role of scavenger receptor A (SR-A) in focal cerebral I/R injury. Both SR-A-/- mice (n=10) and age-matched wild-type (WT) mice (n=9) were subjected to focal cerebral ischemia (60 minutes), followed by reperfusion (for 24 hours). Infarct size was determined by TTC (triphenyltetrazolium chloride) staining. The morphology of neurons in the brain sections was examined by Nissl's staining. Activation of intracellular signaling was analyzed by western blot. Cerebral infarct size in SR-A -/- mice was significantly reduced by 63.9% compared with WT mice after cerebral I/R. In SR-A -/- mice, there was less neuronal damage in the hippocampus compared with WT mice. Levels of FasL, Fas, FADD, caspase-3 activity, and terminal deoynucleotidyl transferase-mediated 2′-deoxyuridine 5′-triphosphate-biotin nick end labeling-positive apoptotic cells were significantly increased in WT mice after cerebral I/R, but not in SR-A -/- mice. Cerebral I/R increased nuclear factor-B activation in WT mice, but not in SR-A -/- mice. These data suggest that SR-A has a central role in cerebral I/R injury and that suppression of SR-A may be a useful approach for ameliorating brain injury in stroke patients.
|
14 |
The Opposing Effects of HDL Metabolism on Prostate CancerTraughber, Cynthia Alicia 07 September 2020 (has links)
No description available.
|
15 |
The Role of Scavenger Receptor-A in Heat Shock Protein 27-mediated Atheroprotection: Mechanistic Insights into a Novel Anti-atherogenic TherapyRaizman, Joshua E. 03 May 2012 (has links)
Heat shock protein (HSP)27 is traditionally described as an intracellular chaperone and signaling molecule, but growing evidence suggests it is released from immune cells where it plays an anti-inflammatory role during atherogenesis. Previously, the O’Brien lab found that overexpression of HSP27 led to augmented HSP27 serum levels in female apolipoprotein E knockout (ApoE-/-) mice, attenuated atherogenesis, and inhibited macrophage foam cell formation via physical binding with scavenger receptor (SR)-A. However, the precise mechanism of atheroprotection remained elusive. This thesis sought to ascertain the mechanism(s) by which HSP27 prevents foam cell formation, and determine if SR-A, a key receptor involved in the uptake of lipid into macrophages, plays an important role in HSP27-mediated atheroprotection. Pre-treatment of human macrophages with recombinant HSP27 (rHSP27) inhibited acytelated low density lipoprotein (acLDL) binding and uptake independent from receptor competition effect. Reduction in uptake was associated with attenuation of expression of SR-A mRNA, total protein, and cell surface expression. To explore the signaling mechanism by which HSP27 modulated SR-A expression it was hypothesized that nuclear factor-kappa B (NF-kB), a major regulator of many atherosclerosis gene programs, is altered by extracellular HSP27. Indeed, rHSP27 markedly activated NF-kB signaling in macrophages. Using an inhibitor of NF-kBsignaling there was an attenuation of rHSP27-induced inhibition of SR-A gene and protein expression, as well as lipid uptake, suggesting that SR-A expression is regulated by NF-kB activation. Lastly, to investigate if SR-A is required for HSP27-mediated atheroprotection in vivo, ApoE-/- and ApoE-/-SR-A-/- mice fed a high fat diet were treated with rHSP25, the mouse orthologue of HSP27, or PBS for 3 weeks. While rHSP25 therapy equally reduced serum cholesterol levels in the mouse cohorts, aortic atherogenesis, assessed using en face and sinus cross-sectional analyses, was attenuated in ApoE-/- mice but not ApoE-/-SR-A-/- mice. In conclusion, rHSP27 inhibits foam cell formation by downregulating SR-A expression. This effect may be associated with NF-kB activation. Reductions in atherosclerotic burden by rHSP27 require SR-A, and are independent of changes in serum cholesterol levels, highlighting the importance of macrophage lipid uptake in atherogenesis. Results presented in this thesis demonstrate that SR-A is a major target for HSP27 atheroprotection in the vessel wall, and provide an impetus for further studies that investigate the potential therapeutic value of HSP27.
|
16 |
THE ROLE OF SCAVENGER RECEPTOR CLASS B TYPE I-REGULATED INDUCIBLE GLUCOCORTICOIDS IN SEPSISAi, Junting 01 January 2014 (has links)
Sepsis claims over 215,000 lives in the US annually. Inducible glucocorticoids (iGC) is produced during sepsis. However, the precise effects of iGC in sepsis remain unclear due to a lack of appropriate animal models. Glucocorticoid (GC) insufficiency is associated with a marked increase in mortality and occurs in 60% of severe septic patients. Yet the conclusion of GC therapy on septic patients is still controversial.
Scavenger receptor class B type I (SR-BI) in the adrenal mediates the selective uptake of cholesteryl ester from lipoproteins for GC synthesis. SR-BI-/- mice completely lack iGC during sepsis and are highly susceptible to septic death, which presents SR-BI-/- mice as a GC insufficient model. However, SR-BI-/- mice display multiple defects contributing to septic death, making it difficult to study iGC by using these mice. Therefore, we utilized adrenal-specific SR-BI-/- mice (ADR-T SR-BI-/-) generated by adrenal transplantation. As expected, the ADR-T SR-BI-/- mice failed to generate iGC under cecal ligation and puncture (CLP)-induced sepsis and showed a significantly higher mortality than the control mice, demonstrating that iGC is essential for preventing septic death. High blood urea nitrogen (BUN) was observed in the ADR-T SR-BI-/- mice but not in the control mice in CLP, indicating that iGC protects kidney injury in sepsis. Plasma IL-6 was remarkably higher in the ADR-T SR-BI-/- mice than the control mice, demonstrating an anti-inflammatory effect of iGC in sepsis. The ADR-T SR-BI-/- mice also displayed significantly lower phagocytic activity of monocytes and neutrophils in the blood and lower activation of T cells in the spleen compared to the control mice in CLP, suggesting that iGC is immunomodulatory in sepsis. Low-dose GC supplementation significantly improved the survival of SR-BI-/- mice in CLP, but did not increase the survival rate of SR-BI+/+ mice in CLP, indicating that GC supplementation improves the survival specifically in mice with adrenal insufficiency.
Overall, we revealed that iGC is essential for sepsis survival. iGC prevents kidney damage, modulates inflammatory responses and exerts immunomodulatory functions in sepsis. GC supplementation specifically improves survival of individuals with adrenal insufficiency in sepsis.
|
17 |
The Role of Scavenger Receptor-A in Heat Shock Protein 27-mediated Atheroprotection: Mechanistic Insights into a Novel Anti-atherogenic TherapyRaizman, Joshua E. 03 May 2012 (has links)
Heat shock protein (HSP)27 is traditionally described as an intracellular chaperone and signaling molecule, but growing evidence suggests it is released from immune cells where it plays an anti-inflammatory role during atherogenesis. Previously, the O’Brien lab found that overexpression of HSP27 led to augmented HSP27 serum levels in female apolipoprotein E knockout (ApoE-/-) mice, attenuated atherogenesis, and inhibited macrophage foam cell formation via physical binding with scavenger receptor (SR)-A. However, the precise mechanism of atheroprotection remained elusive. This thesis sought to ascertain the mechanism(s) by which HSP27 prevents foam cell formation, and determine if SR-A, a key receptor involved in the uptake of lipid into macrophages, plays an important role in HSP27-mediated atheroprotection. Pre-treatment of human macrophages with recombinant HSP27 (rHSP27) inhibited acytelated low density lipoprotein (acLDL) binding and uptake independent from receptor competition effect. Reduction in uptake was associated with attenuation of expression of SR-A mRNA, total protein, and cell surface expression. To explore the signaling mechanism by which HSP27 modulated SR-A expression it was hypothesized that nuclear factor-kappa B (NF-kB), a major regulator of many atherosclerosis gene programs, is altered by extracellular HSP27. Indeed, rHSP27 markedly activated NF-kB signaling in macrophages. Using an inhibitor of NF-kBsignaling there was an attenuation of rHSP27-induced inhibition of SR-A gene and protein expression, as well as lipid uptake, suggesting that SR-A expression is regulated by NF-kB activation. Lastly, to investigate if SR-A is required for HSP27-mediated atheroprotection in vivo, ApoE-/- and ApoE-/-SR-A-/- mice fed a high fat diet were treated with rHSP25, the mouse orthologue of HSP27, or PBS for 3 weeks. While rHSP25 therapy equally reduced serum cholesterol levels in the mouse cohorts, aortic atherogenesis, assessed using en face and sinus cross-sectional analyses, was attenuated in ApoE-/- mice but not ApoE-/-SR-A-/- mice. In conclusion, rHSP27 inhibits foam cell formation by downregulating SR-A expression. This effect may be associated with NF-kB activation. Reductions in atherosclerotic burden by rHSP27 require SR-A, and are independent of changes in serum cholesterol levels, highlighting the importance of macrophage lipid uptake in atherogenesis. Results presented in this thesis demonstrate that SR-A is a major target for HSP27 atheroprotection in the vessel wall, and provide an impetus for further studies that investigate the potential therapeutic value of HSP27.
|
18 |
The Role of Scavenger Receptor-A in Heat Shock Protein 27-mediated Atheroprotection: Mechanistic Insights into a Novel Anti-atherogenic TherapyRaizman, Joshua E. January 2012 (has links)
Heat shock protein (HSP)27 is traditionally described as an intracellular chaperone and signaling molecule, but growing evidence suggests it is released from immune cells where it plays an anti-inflammatory role during atherogenesis. Previously, the O’Brien lab found that overexpression of HSP27 led to augmented HSP27 serum levels in female apolipoprotein E knockout (ApoE-/-) mice, attenuated atherogenesis, and inhibited macrophage foam cell formation via physical binding with scavenger receptor (SR)-A. However, the precise mechanism of atheroprotection remained elusive. This thesis sought to ascertain the mechanism(s) by which HSP27 prevents foam cell formation, and determine if SR-A, a key receptor involved in the uptake of lipid into macrophages, plays an important role in HSP27-mediated atheroprotection. Pre-treatment of human macrophages with recombinant HSP27 (rHSP27) inhibited acytelated low density lipoprotein (acLDL) binding and uptake independent from receptor competition effect. Reduction in uptake was associated with attenuation of expression of SR-A mRNA, total protein, and cell surface expression. To explore the signaling mechanism by which HSP27 modulated SR-A expression it was hypothesized that nuclear factor-kappa B (NF-kB), a major regulator of many atherosclerosis gene programs, is altered by extracellular HSP27. Indeed, rHSP27 markedly activated NF-kB signaling in macrophages. Using an inhibitor of NF-kBsignaling there was an attenuation of rHSP27-induced inhibition of SR-A gene and protein expression, as well as lipid uptake, suggesting that SR-A expression is regulated by NF-kB activation. Lastly, to investigate if SR-A is required for HSP27-mediated atheroprotection in vivo, ApoE-/- and ApoE-/-SR-A-/- mice fed a high fat diet were treated with rHSP25, the mouse orthologue of HSP27, or PBS for 3 weeks. While rHSP25 therapy equally reduced serum cholesterol levels in the mouse cohorts, aortic atherogenesis, assessed using en face and sinus cross-sectional analyses, was attenuated in ApoE-/- mice but not ApoE-/-SR-A-/- mice. In conclusion, rHSP27 inhibits foam cell formation by downregulating SR-A expression. This effect may be associated with NF-kB activation. Reductions in atherosclerotic burden by rHSP27 require SR-A, and are independent of changes in serum cholesterol levels, highlighting the importance of macrophage lipid uptake in atherogenesis. Results presented in this thesis demonstrate that SR-A is a major target for HSP27 atheroprotection in the vessel wall, and provide an impetus for further studies that investigate the potential therapeutic value of HSP27.
|
19 |
The role of CD5 in T lymphocyte activationLacey, Erica January 2011 (has links)
No description available.
|
20 |
Participação do PAF-R na fagocitose de células apoptóticas, no fenótipo de macrófagos e na imunossupressão causada por terapia fotodinâmica. / Participation of PAF-R in the phagocytosis of apoptotic cells, in macrophage phenotype and in the immunosuppression caused by photodynamic therapy.Ferracini, Matheus 18 September 2014 (has links)
Macrófagos (Mf) produzem PAF e PAF-R e eliminam partículas alteradas via CD36. Uptake de oxLDL requer associação CD36/PAF-R. Avaliamos isto na eferocitose. Bloqueio do PAF-R e de lipid rafts (LR) inibiu eferocitose. Esta induziu associação PAF-R/CD36 e destes com flotilina-1 (marca LR). Eferocitose induziu IL-10 e IL-12p40. Bloqueio do PAF-R inibiu mais IL-10 e inibição da COX-2 teve efeito similar, sugerindo que eferocitose depende da interação PAF-R/CD36 em LR e que isto induz prostanoides e perfil regulador. Mf adquirirem diferentes fenótipos. Estudamos a participação do PAF-R. Bloqueio do PAF-R antes dos estímulos (IFN-g/LPS, IL-4 ou IgG-SRBC/LPS) inibiu marcadores MCP-1, TNF-a, iNOS, receptor manose, arginase-1 e IL-10, mas não IL-12p40, sugerindo que PAF-R modula fenótipo de Mf. PAF e PAF-like são gerados por estressores oxidativos. Ativação do PAF-R induz imunossupressão sistêmica (IS). Mostramos que terapia fotodinâmica (PDT) in vitro gerou ligantes do PAF-R e in vivo inibiu reação de CHS em WT, mas não em PAF-R KO, sugerindo que PDT induz IS via PAF-R. / Macrophages (Mp) produce PAF and PAF-R and scavenge altered particles via CD36. oxLDL uptake requires association CD36/PAF-R. We analyzed that on efferocytosis. PAF-R and lipid rafts (LR) blockage inhibited efferocytosis. Efferocytosis induced association CD36/PAF-R and both with LR marker protein, and induced IL-10 and IL-12p40. PAF-R and COX-2 blockage inhibited more IL-10, suggesting that efferocytosis depends on PAF-R/CD36 interaction in LR and that this induces prostanoids and regulatory profile. Mp acquire different phenotypes. PAF-R participation in that was analyzed. PAF-R blockage before stimuli (IFN-g/LPS, IL-4 or IgG-SRBC/LPS) inhibited markers MCP-1, TNF-a, iNOS, mannose receptor, arginase-1 and IL-10, but not IL-12p40, suggesting that PAF-R modulates Mp phenotype. PAF and PAF-like are generated by oxidative stressors. PAF-R activation induces systemic immunosuppression (SI). We showed that photodynamic therapy (PDT) in vitro generated PAF-R ligands and in vivo inhibited CHS reaction in WT, but not PAF-R KO, suggesting that PDT induces SI via PAF-R.
|
Page generated in 0.0867 seconds